What is United Therapeutics's market cap?

United Therapeutics (UTHR) has a market capitalization of $21.5B and trades on NASDAQ.

What is United Therapeutics's revenue and profitability?

United Therapeutics generated $3.2B in trailing twelve-month revenue with net income of $1.3B, representing a net margin of 41.6%. Gross margin stands at 86.1%, with free cash flow of $1.1B. The latest reported period is Q2 2026.

Who are United Therapeutics's competitors?

United Therapeutics's key competitors include Merck & Co., Inc., Johnson & Johnson, Gossamer Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does United Therapeutics partner with?

United Therapeutics's notable partners include MannKind Corporation, DEKA Research & Development Corp., Eli Lilly and Company, and others.

Where is United Therapeutics headquartered?

United Therapeutics is headquartered in United States of America and employs approximately 1,168 people. It has been publicly traded since 1999.

United Therapeutics (UTHR) Stock Fundamentals & Financials

United Therapeutics is a biotechnology company and public benefit corporation dedicated to developing novel pharmaceutical therapies for rare diseases and innovative organ manufacturing technologies.

Market cap

$21.46B+17.5%

Revenue$3.2B+2.5%

Net income$1.3B+5.5%

Free cash flow$1.1B+2.1%

EPS (diluted)$27.94+9.0%

Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 5, 2026

Revenue$783.3MMiss by $21.3M EPS$7.27Beat by $0.41

Read the full report

Next report

Nov 4, 2026 (in 2 months)

Revenue estimate$789.5M

EPS estimate$6.44

Financials

Q2 2026

Income statement

See full

Revenue$783.3M-1.9%

Gross profit$683.8M-3.8%

Operating income$330.8M-9.2%

Net income$333.0M+7.6%

EPS (diluted)$7.27+13.4%

Balance sheet

See full

Cash & equivalents$1.8B+13.2%

Total equity$6.4B-10.8%

Total assets$7.2B-8.7%

Cash flow

See full

Operating cash flow$313.6M+63.6%

CapEx$108.0M+73.6%

Free cash flow$205.6M+58.8%

Valuation & ratios

Valuation

See full

Market cap$21.46B+17.5%

P/E16.4×+1.9×

P/S6.8×+1.0×

Profitability

See full

Gross margin86.1%-2.8pp

Operating margin44.4%-2.6pp

Net margin41.6%+1.2pp

FCF margin34.6%-0.1pp

Returns & leverage

See full

Return on equity19.3%0.0pp

Current ratio5.7×-1.5×

Segments

By product

See full

Tyvaso DPI$326.6M+3.6%

Remodulin$126.3M-6.2%

Nebulized Tyvaso$126.0M-18.4%

Orenitram$125.7M+1.5%

Unituxin$65.2M+11.6%

Competitors

By market cap

Johnson & Johnson$643.92B+51.5%

Merck & Co.$354.75B+75.1%

Amgen$203.09B+38.1%

United Therapeutics$21.5B+19.2%

LQD

Liquidia Corporation$5.9B+163%

Theravance Biopharma$884.7M+26.7%

Inhibikase Therapeutics, Inc.$322.3M+177%

Gossamer Bio, Inc.$63.4M-91.3%

By revenue growth

LQD

Liquidia Corporation+2,234%

Theravance Biopharma+35.1%

Amgen+9.1%

Johnson & Johnson+8.1%

Merck & Co.+4.6%

United Therapeutics+2.5%

By net margin

Theravance Biopharma51.58%+34.7pp

United Therapeutics41.56%+1.2pp

Amgen22.95%+4.0pp

Johnson & Johnson21.48%-3.5pp

Merck & Co.4.77%-21.0pp

LQD

Liquidia Corporation-176.24%+725pp

Profile

United Therapeutics is a biotechnology company and public benefit corporation dedicated to developing novel pharmaceutical therapies for rare diseases and innovative organ manufacturing technologies. The company primarily focuses on treating pulmonary arterial hypertension (PAH) and other chronic lung diseases while engineering an unlimited supply of transplantable organs. Their core value proposition lies in providing life-sustaining treatments for patients with unmet medical needs through drug-device combinations and advanced regenerative medicine.

Competitive position

A leading player in the PAH market with a dominant position in treprostinil-based therapies and a pioneer in the emerging field of xenotransplantation.

GeographiesUnited States, Japan, Europe, Canada

Customer segmentsSpecialty Distributors, Healthcare Providers, Rare Disease Patients

Business modelProduct-based, Research and Development, Licensing

SuppliersContract manufacturers, Active pharmaceutical ingredient suppliers, Medical device component manufacturers, Gene-editing technology providers

CustomersSpecialty pharmaceutical distributors, Hospitals, Specialty pharmacies, End-stage organ failure patients

CountryUnited States of America

Listed1999

Employees1.2K

CEOMartine A. Rothblatt

SectorHealthcare

IndustryBiotechnology

Websiteunither.com

FilingsSEC EDGAR

FAQ

What is United Therapeutics's market cap?: United Therapeutics (UTHR) has a market capitalization of $21.5B and trades on NASDAQ.
What is United Therapeutics's revenue and profitability?: United Therapeutics generated $3.2B in trailing twelve-month revenue with net income of $1.3B, representing a net margin of 41.6%. Gross margin stands at 86.1%, with free cash flow of $1.1B. The latest reported period is Q2 2026.
Who are United Therapeutics's competitors?: United Therapeutics's key competitors include Merck & Co., Inc., Johnson & Johnson, Gossamer Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does United Therapeutics partner with?: United Therapeutics's notable partners include MannKind Corporation, DEKA Research & Development Corp., Eli Lilly and Company, and others.
Where is United Therapeutics headquartered?: United Therapeutics is headquartered in United States of America and employs approximately 1,168 people. It has been publicly traded since 1999.

Ask your AI about United Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude